RxDoctor Payments Data

James Strauss

Medical Oncology · Dallas, TXNPI 1770525933

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Restor3d, Inc.. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.

$23in general payments, 2019–2025

Across 1 payment — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Restor3d, Inc.$23
$9,089,238in research payments, 2019–2025

Across 1,282 payments — averaging $7089.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$3.2M
  • Pfizer$1.2M
  • Alkermes, Inc.$1M
  • GSK$922K
  • Takeda Pharmaceuticals U.S.A., Inc.$665K
  • Epizyme, Inc.$438K
  • plus $1.6M from 12 others

What the payments were for

  • Food & beverage$23100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Restor3d, Inc.1$23

How this compares

$23 in reported general payments places this provider in the 0th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Other medical oncology in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →